BRISTOL MYERS SQUIBB
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- -
- Established
- 1989-01-01
- Employees
- 30K
- Market Cap
- $97.5B
- Website
- https://www.bms.com/
Exelixis Reports Promising Results for Zanzalintinib Combination in Advanced Kidney Cancer
• Zanzalintinib combined with nivolumab demonstrated a 63% objective response rate and 90% disease control rate in previously untreated advanced clear cell renal cell carcinoma patients.
• The combination therapy showed durable responses with a 12-month duration of response of 73.4% and median progression-free survival of 18.5 months in the nivolumab arm.
• Results from the STELLAR-002 trial will be presented at the 2025 American Society of Clinical Oncology Annual Meeting, supporting further evaluation of zanzalintinib-based regimens.
Dementia Discovery Fund Secures $269M in Second Fund to Accelerate Novel Therapeutics Development
• The Dementia Discovery Fund (DDF), managed by SV Health Investors, has closed its second fund with $269 million in commitments, bringing its total raised capital to over $550 million for dementia therapeutics development.
• The fund has secured backing from previous cornerstone investors including AARP, British Business Bank, Gates Frontier, pharmaceutical giants Bristol Myers Squibb, Eli Lilly, and Pfizer, with the Alzheimer's Association joining as a new investor.
• DDF-2 has already invested in four companies and aims to build a portfolio of 10-15 innovative biotech ventures across the UK, Europe, and US, addressing the urgent global challenge of dementia affecting over 50 million people worldwide.
Tubulis and Bristol Myers Squibb Advance First Collaborative Tubutecan ADC into Clinical Trials
• Tubulis announced that the first antibody-drug conjugate from its strategic partnership with Bristol Myers Squibb has entered clinical development, marking a significant milestone in their 2023 collaboration agreement.
• The ADC candidate leverages Tubulis' proprietary Tubutecan technology, which combines their P5 conjugation system with an exatecan payload to create stable, targeted cancer therapeutics with minimized systemic toxicity.
• This represents the third Tubutecan-based ADC to reach clinical trials within 12 months, following Tubulis' wholly owned programs TUB-030 and TUB-040, demonstrating the platform's versatility for treating solid tumors.
Accropeutics' Oral TYK2/JAK1 Inhibitor Shows Strong Efficacy in Phase 2 Psoriasis Trial
• AC-201, an oral selective TYK2/JAK1 inhibitor, met its primary endpoint with up to 74.3% of patients achieving PASI-75 responses at week 12 across all three dosing regimens tested.
• The drug demonstrated a favorable safety profile with no serious adverse events or discontinuations, positioning it as a potentially competitive option in the growing market for oral psoriasis treatments.
• Based on these positive Phase 2 results, Accropeutics plans to advance AC-201 into Phase 3 development for plaque psoriasis, with potential applications in other autoimmune conditions.
Bristol Myers Squibb to Close Gene Therapy Manufacturing Facility in Libertyville, Illinois
• Bristol Myers Squibb has announced the closure of its viral vector production facility in Libertyville, Illinois, with operations being consolidated to Devens, Massachusetts, as part of a $2 billion cost-saving initiative.
• The facility, which was acquired by Bristol Myers Squibb two years ago and previously used by Novartis to manufacture the gene therapy Zolgensma, will begin layoffs on July 1 according to state WARN reports.
• Company representatives acknowledged the difficult decision to cease vector manufacturing at the Libertyville site, which they noted "has operated at the highest level for BMS Cell Therapy."
Pfizer Enters $6 Billion Licensing Deal with China's 3SBio for Novel Cancer Drug
• Pfizer has secured global rights (excluding China) to 3SBio's experimental cancer drug SSGJ-707 for $1.25 billion upfront, with potential additional payments of up to $4.8 billion based on developmental milestones.
• SSGJ-707 is currently being evaluated for multiple cancer types including non-small cell lung cancer, metastatic colorectal cancer, and gynecological tumors, with Phase III trials in China planned to begin this year.
• The deal includes a $100 million equity investment in 3SBio by Pfizer, with manufacturing planned at Pfizer's facilities in North Carolina and Kansas following FDA clearance of the Investigational New Drug application.
CellCentric Secures $120 Million Series C Funding to Advance Oral Multiple Myeloma Treatment
• CellCentric has raised $120 million in Series C funding to advance inobrodib, a first-in-class oral p300/CBP inhibitor for multiple myeloma treatment.
• The funding will support a Phase II/III study with potential for accelerated approval, as well as trials combining inobrodib with bi-specific antibodies and in maintenance settings.
• Inobrodib has received FDA Fast Track and orphan drug designation, with promising efficacy and safety data presented at the American Society of Hematology Annual Meeting.
Prime Medicine Restructures: CEO Replaced, 25% Staff Cut, and Lead Program Halted
• Prime Medicine announced a major restructuring on Monday, replacing its CEO, laying off 25% of staff, and discontinuing its only clinical program despite previous scientific milestones.
• The company's decision reflects broader challenges in the gene editing sector, where numerous firms have reduced workforce or terminated programs during an extended industry downturn.
• This reorganization highlights the disconnect between promising early scientific data and commercial viability in the advanced therapeutic space, particularly for CRISPR-based technologies.
Prime Medicine Reports Breakthrough Clinical Data for First Prime Editing Therapy in Chronic Granulomatous Disease
• Prime Medicine's PM359, the first Prime Editing therapy administered to humans, demonstrated rapid restoration of NADPH oxidase activity in a patient with Chronic Granulomatous Disease, exceeding therapeutic thresholds.
• A single infusion of PM359 achieved 66% DHR positivity by Day 30, significantly above the 20% threshold believed to be potentially curative, with faster engraftment than existing gene editing technologies.
• The therapy showed an encouraging safety profile with no serious adverse events related to PM359, marking a significant milestone for Prime Editing technology as a potential one-time curative treatment for genetic diseases.
CytomX Doses First Patient in Combination Trial of CX-801 with Keytruda for Metastatic Melanoma
• CytomX Therapeutics has dosed the first patient in a Phase 1 trial combining its masked interferon alpha-2b (CX-801) with Merck's Keytruda in patients with metastatic melanoma.
• The novel combination aims to address the high unmet need in PD-1 refractory melanoma by localizing interferon's potent immune-stimulating effects to tumors while minimizing systemic toxicities.
• Initial Phase 1a translational and biomarker data from this study are expected in the second half of 2025, potentially advancing a new approach in combination immuno-oncology therapy.
Prime Medicine Advances Gene Editing Pipeline with Key Programs for CGD, Wilson's Disease, and AATD
• Prime Medicine expects to release initial clinical data from its Phase 1/2 trial of PM359 for p47phox chronic granulomatous disease in 2025, potentially demonstrating the curative potential of its Prime Editing technology.
• The company recently unveiled its alpha-1 antitrypsin deficiency (AATD) program, which has shown promising preclinical results with high editing efficiency and full restoration of wild-type AAT protein to normal human range.
• Prime Medicine is advancing its Wilson's Disease program (PM577) through IND-enabling studies, with regulatory filings planned for first half of 2026, as part of its expanding liver disease franchise.
Pfizer to Showcase Breakthrough Cancer Therapies at ASCO 2025 with Over 60 Presentations
• Pfizer will present data from more than 60 abstracts at ASCO 2025, including 15 oral presentations highlighting advancements across breast, genitourinary, hematologic, thoracic, and colorectal cancers.
• Two late-breaking presentations will be featured in ASCO's press program, including pivotal survival data for BRAFTOVI in colorectal cancer and progression-free survival results for vepdegestrant in metastatic breast cancer.
• The company will showcase novel antibody-drug conjugate combinations with immunotherapy and present five-year survival data for XTANDI in prostate cancer, supporting Pfizer's goal of delivering eight breakthrough cancer medicines by 2030.
Robust Pipeline of 80+ Therapies Advancing in Psoriasis Treatment Landscape
• DelveInsight's 2025 Psoriasis Pipeline Report reveals over 80 companies developing 80+ pipeline therapies, highlighting significant R&D investment in this therapeutic area.
• Promising treatments in development include topical roflumilast (Arcutis Biotherapeutics) in Phase III trials and GSK2982772 (GlaxoSmithKline), a novel RIPK1 inhibitor in Phase I development.
• Alumis Inc. has initiated a long-term extension study for ESK-001 in moderate to severe plaque psoriasis patients, evaluating safety, efficacy, and durability of response over 24 weeks.
Brain Hemorrhage Treatment Market Expected to Grow Significantly by 2032 as AI Solutions Gain FDA Approval
• The brain hemorrhage treatment market is projected to experience substantial growth through 2032, driven by an aging population and increasing prevalence of risk factors such as hypertension and traumatic brain injuries.
• Recent FDA approvals for AI-based diagnostic tools, including JLK-LVO and Heuron ICH, mark significant advancements in early detection and treatment of brain hemorrhages.
• Several pharmaceutical companies including Baxter, Pfizer, and Novartis are developing promising pipeline therapies such as tissue plasminogen activator, alteplase, and BAF312 to address the significant unmet needs in brain hemorrhage treatment.
UK Government Maintains High Pharmaceutical Rebate Rates Despite Industry Pushback
• The UK government has maintained historically high rebate rates for pharmaceutical companies under the statutory scheme, setting rates at 21.9% in 2024, 24% in 2025, and 26.8% in 2026.
• The Association of the British Pharmaceutical Industry (ABPI) criticizes the decision, arguing these rates damage the UK's international standing and send "confusing messages" to global life sciences investors.
• While the voluntary scheme (VPAG) was recently renegotiated to industry satisfaction, companies opting for the statutory scheme face rebate rates significantly higher than comparable European markets like Germany (12%), Spain (7.5%), and Ireland (8.25%).
GSK's Blenrep Secures UK Approval for Multiple Myeloma Treatment in Combination Therapy
• The UK's medicines regulatory body has approved GSK's Blenrep (belantamab mafodotin) in combination with other drugs for multiple myeloma patients whose first treatment failed or caused severe side effects.
• This approval marks a significant comeback for Blenrep, which was withdrawn from markets in 2022 after failing to outperform existing treatments when used as monotherapy.
• Clinical trials demonstrated Blenrep's combination therapy extended progression-free survival and overall survival compared to standard care regimens, including those based on Darzalex (daratumumab).
Roche Expands Molecular Glue Portfolio with $2 Billion Monte Rosa Partnership
• Roche has signed a $2 billion partnership with Monte Rosa Therapeutics, including a $50 million upfront payment, to develop molecular glue therapies targeting previously "undruggable" proteins in cancer and neurological diseases.
• This marks Roche's second major molecular glue deal in a month, following a similar $2 billion alliance with Orionis Biosciences, demonstrating the company's strategic push to establish leadership in this emerging therapeutic category.
• Monte Rosa will lead discovery and preclinical activities using its QuEEN platform, with Roche taking over late-stage development of candidates that can potentially address the 80% of human proteins currently inaccessible to traditional drug development approaches.
Landmark CheckMate 816 Trial: Nivolumab-Chemotherapy Combo Shows Survival Benefit in Resectable Lung Cancer
• Neoadjuvant nivolumab plus platinum-doublet chemotherapy demonstrates statistically significant overall survival improvement in resectable non-small cell lung cancer patients compared to chemotherapy alone.
• The groundbreaking phase 3 CheckMate 816 trial establishes the first neoadjuvant immunotherapy combination to achieve significant survival benefits, with previously reported 24% pathological complete response rate.
• The treatment combination maintains a consistent safety profile with no new concerns, while showing improved efficacy in both neoadjuvant and perioperative settings for resectable NSCLC patients.
Novel Oral Psoriasis Therapies Show Promise: TYK2 Inhibitors Lead Breakthrough Advances
• Deucravacitinib demonstrates superior efficacy over apremilast in psoriasis treatment, with over 53% of patients achieving significant skin clearance at week 16.
• Apremilast maintains its position as a key therapy for mild-to-moderate psoriasis, with 21% of bio-naïve patients achieving treatment goals in the ADVANCE trial.
• Next-generation oral therapies, including JNJ-77242114 and zasocitinib, show promising results in clinical trials, potentially expanding treatment options for psoriasis patients.
Gastrointestinal Cancer Symposium 2025: Key Advances in Treatment Strategies
• Nivolumab plus ipilimumab demonstrates superior progression-free survival compared to nivolumab alone in MSI-H/dMMR metastatic colorectal cancer.
• Encorafenib combined with cetuximab and chemotherapy shows significant improvement in overall response rate for BRAF V600E-mutated metastatic colorectal cancer.
• TACE plus camrelizumab and rivoceranib extends progression-free survival in patients with unresectable hepatocellular carcinoma, offering a manageable safety profile.
© Copyright 2025. All Rights Reserved by MedPath